GlassScriptPhysician profile
Michelle S Gerdes
NPI 1376566380
$19,884.85
in general payments reported to CMS, 2019-2025
40 companies · $3,467 in 2025
The $3,467 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,781 · 2020: $1,760 · 2021: $2,690 · 2022: $3,863 · 2023: $3,438 · 2024: $2,887 · 2025: $3,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,592 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,592.18 |
| Education | $199.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,377.05 | 2019-2025 | |
| Lilly USA, LLC | $1,699.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $1,447.12 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,377.17 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,315.94 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Novartis Pharmaceuticals Corporation | $1,268.32 | 2019-2025 | |
| Genzyme Corporation | $1,158.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,011.68 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $913.00 | 2019-2025 | Nemluvio, Dysport, Aklief |
| E.R. Squibb & Sons, L.L.C. | $779.22 | 2022-2025 | Sotyktu |
| Ucb, INC. | $630.14 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $493.63 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $463.24 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $377.32 | 2023-2025 | Zoryve |
| Almirall LLC | $319.30 | 2019-2025 | Seysara, Klisyri |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $296.22 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $292.75 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $252.12 | 2019-2025 | |
| Dermavant Sciences, INC. | $226.11 | 2022-2024 | Vtama |
| Genentech USA, INC. | $214.14 | 2019-2022 | |
| Journey Medical Corporation | $163.44 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.45 | 2019-2025 | Jublia, Siliq, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $99.58 | 2021-2025 | Genadur, Neo-Synalar |
| Biofrontera INC. | $81.28 | 2019-2022 | |
| Elekta, INC. | $47.02 | 2025 | Flexitron Hdr |
| Vyne Pharmaceuticals INC. | $46.12 | 2020-2021 | |
| Botanix Sb INC | $42.11 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $39.38 | 2022-2023 | Valchlor |
| Dermira, INC. | $38.13 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $36.64 | 2024-2025 | Nuzyra |
| Verrica Pharmaceuticals INC. | $36.17 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.76 | 2023-2024 | Cyltezo |
| Ani Pharmaceuticals, INC. | $33.05 | 2023 | Apexicon E |
| Hill Dermaceuticals, INC. | $32.27 | 2023-2024 | Tolak |
| Epi Health, LLC | $28.03 | 2019-2020 | |
| Organon LLC | $25.13 | 2025 | Hadlima |
| Allergan, INC. | $15.72 | 2019 | |
| Aclaris Therapeutics, INC. | $13.55 | 2019 | |
| Celgene Corporation | $13.50 | 2019 | |
| Icad, INC | $13.40 | 2023 | Axxent Surface Controller |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gerdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.